The recent announcement by the Centers for Disease Control and Prevention (CDC) regarding the limited availability of the RSV vaccine, Beyfortus (nirsevimab), has raised significant concerns among parents and healthcare providers alike. With the onset of RSV season, the CDC advises prioritizing this vaccine for very young infants who are at the highest risk of
0 Comments